Q2 2025 Management View William J. Sibold, CEO, highlighted a "productive last few months" focused on driving the launch and building for the future, noting, "Rezdiffra’s quarterly run rate now ...

Madrigal Pharmaceuticals (MDGL) stock gains as the company's Q2 2025 results exceed expectations with a 15-fold surge in ...

Las Vegas(KLAS)-TV Personality, Peter Madrigal, has launched ‘Reality Network’ providing a one stop shop for all things ...

Second-quarter 2025 Rezdiffra™ (resmetirom) net sales of $212.8 millionAs of June 30, 2025, more than 23,000 patients on Rezdiffra Received new U.S. Rezdiffra patent providing protection to Feb. 4, ...

Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

WEST CONSHOHOCKEN, Pa. (AP) — WEST CONSHOHOCKEN, Pa. (AP) — Madrigal Pharmaceuticals Inc. (MDGL) on Tuesday reported a loss of $42.3 million in its second quarter. The West Conshohocken, ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...

Scheana Shay's candid comments about her falling out with Lisa Vanderpump upset one of her former Vanderpump Rules costars.